Home

arrow iconNewsarrow iconarrow icon

Legacy Earns New York State CLEP Approval for Its DNA Fragmentation Test and Semen Analysis

Legacy Earns New York State CLEP Approval for Its DNA Fragmentation Test and Semen Analysis

Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.

By FertilityIn

12 Oct 2026

1 min read

 Legacy Earns New York State CLEP Approval for Its DNA Fragmentation Test and Semen Analysis

Legacy, a leading male fertility testing and sperm preservation company, has announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP), administered by the Wadsworth Center, has formally validated and approved two of its laboratory-developed tests: semen analysis and sperm DNA fragmentation analysis.


The milestone places Legacy in rare company. New York operates the only programme in the United States that requires each laboratory-developed test (LDT) to clear a formal, mandatory pre-market review before being offered to patients in the state. Clearing that bar for a single test is a significant achievement. Clearing it for both core andrology assays simultaneously, semen analysis and the DNA fragmentation test, is a statement about the clinical rigour behind Legacy's entire testing platform.


Why New York's Standard Is Different

Most US states do not require laboratory-developed tests to undergo pre-market regulatory scrutiny before reaching patients. New York's CLEP programme is the exception – a system that mandates independent validation of each LDT's methodology, analytical performance, and clinical applicability before results from that test can be reported to patients in the state.


For Legacy, which built its model around at-home sample collection and mail-in delivery to its CLIA-certified andrology laboratory in New Jersey, obtaining CLEP approval for tests performed on home-collected samples carries particular weight. Both approved tests are validated specifically for use on samples collected at home and returned to Legacy's laboratory – not clinic-collected samples operating under controlled conditions but real-world specimens handled by patients themselves.


"New York is arguably the most rigorous state-based evaluation of laboratory testing methodology in the country," said Dr. Scott Lundy, Chief Medical Officer of Legacy. "Obtaining certification for both semen analysis and DNA fragmentation reaffirms our commitment to clinical excellence and provides strong evidence of the clinical validity of our at-home test relative to the gold standard."


Two Tests. One Comprehensive Picture

The two CLEP-approved assays sit at the heart of Legacy's clinical offering – and together, they cover complementary dimensions of male reproductive health.


Semen Analysis evaluates the core parameters of sperm function:



The DNA Fragmentation Test goes a critical step further. Where standard semen analysis evaluates physical sperm parameters, the DNA fragmentation test measures the integrity of the genetic material that sperm carries, a dimension of sperm health that standard analysis does not capture and that can be elevated even in men whose routine semen parameters appear normal.


Sperm DNA fragmentation refers to breaks or damage in the DNA strands within individual sperm cells. High levels have been associated with male infertility, recurrent pregnancy loss, and poor IVF outcomes. For patients and clinicians attempting to understand why conception or IVF is failing despite apparently normal semen parameters, the DNA fragmentation test provides a layer of diagnostic insight that standard analysis simply cannot.


Together, the two CLEP-approved tests give New York patients and their physicians a genuinely comprehensive picture of male fertility, one derived from a sample collected at home, without a clinic visit.


The Significance for New York Patients

For patients in New York, the approvals remove a barrier that has existed since Legacy began expanding its at-home testing platform. CLEP approval means that results from Legacy's semen analysis and DNA fragmentation test can now be formally reported to patients in New York State – with the backing of the country's most demanding independent LDT review process.


Khaled Kteily, founder and CEO of Legacy, put it plainly:


"New York sets the highest bar in the country for laboratory testing, and clearing its review for an individual test is its own milestone. Having both our semen analysis and DNA fragmentation tests approved means a New Yorker can get a clinical-grade result without leaving home and trust that it has been validated against the most rigorous standard that exists. That's the kind of access we've spent years building toward."

117 views

Share

FertilityIn

Send Enquiry for this Story

Related Articles

Fertility Treatment Coverage Gap Revealed by Stork Foundation

Fertility Treatment Coverage Gap Revealed by Stork Foundation

The Stork Foundation for Infertility received a record 1,076 grant applications in 2026, with data revealing that 85% of applicants have no fertility treatment coverage for the care they are pursuing. Average anticipated next treatment costs stand at 19,149 USD, with 39% having already spent more than 10,000 USD out of pocket.

ART

1 min read

Future Health Abu Dhabi Opens Digital Health Innovation Challenge 2026

Future Health Abu Dhabi Opens Digital Health Innovation Challenge 2026

Future Health, A Global Initiative by Abu Dhabi has launched the Future Health Digital Health Innovation Challenge 2026, inviting global innovators to develop AI, software, and connected technology solutions across fertility, population health, and well-being. Three finalists will share USD 105,000 at GITEX 2026, with selected solutions eligible for incubation and scale.

ART

1 min read

La Trobe University and GonGlobal Partner to Advance AI-Driven Fertility Care Through Digital Twin Technology

La Trobe University and GonGlobal Partner to Advance AI-Driven Fertility Care Through Digital Twin Technology

La Trobe University and GonGlobal have entered a strategic collaboration to develop and validate AI and digital twin technologies for ART and IVF. The partnership will build AI-driven fertility care tools, including cohort matching digital twins and deep-learning models, to predict pregnancy outcomes and support personalised clinical decision-making.

ART

1 min read

The World Egg and Sperm Bank Joins IVI Institute to Widen Access to Reproductive Solutions Globally

The World Egg and Sperm Bank Joins IVI Institute to Widen Access to Reproductive Solutions Globally

IVI Institute has announced the acquisition of The World Egg and Sperm Bank (TWESB), founded in 2004 and operating from Scottsdale, Arizona. The move expands access to reproductive solutions for patients and clinics across the United States and Australia, combining TWESB’s network of 500+ screened donors with IVI Institute’s global clinical and scientific infrastructure.

ART

1 min read

UK’s First Testicular Tissue Transplant Offers Hope for Fertility Preservation

UK’s First Testicular Tissue Transplant Offers Hope for Fertility Preservation

Doctors at NHS Lothian in Edinburgh have performed the UK’s first testicular tissue transplant, reimplanting tissue frozen before chemotherapy in a 19-year-old patient with a serious blood disorder. The testicular tissue transplant, only the second reported worldwide, could eventually give thousands of young boys a realistic path to future fatherhood.

ART

1 min read

AiVA AI Assistant: IVI RMA Launches Fertility AI Platform

AiVA AI Assistant: IVI RMA Launches Fertility AI Platform

Flora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world’s leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue’s community of over 100 million members gains early exposure to proactive fertility financial planning.

ART

1 min read

WHO Issues First Global Guideline on Infertility Care

WHO Issues First Global Guideline on Infertility Care

The World Health Organization releases its first comprehensive, evidence-based global guideline for infertility prevention, diagnosis, and treatment. Addressing one in six people of reproductive age worldwide, the guideline emphasizes equity, human rights, and standardized interventions to improve access to fertility care globally.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address